Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment.

Demonstrating that Gen Z and Gen Alpha students embody "STEMpathy"—the fusion of STEM (Science, Technology, Engineering, and Mathematics) skills and a compassionate drive to solve community challenges ...

Under a settlement inked with J&J in late 2023, Samsung Bioepis and Sandoz got the all-clear to launch their Stelara biosimilar from Feb. 22, 2025. The settlement is one of many J&J has inked over ...

How to fix Samsung Galaxy J3 that won’t bootup or turn on after a firmware update [Troubleshooting Guide & Potential Solutions] How to boot your Samsung Galaxy J3 in safe mode, recovery mode ...

Welcome to our Galaxy J7 Troubleshooting page, which contains all the links to problems, issues, questions, tutorials, FAQs, how to’s and guides that you can use.

RIDGEFIELD PARK, N.J. & LUBBOCK, Texas--(BUSINESS WIRE)--Samsung has partnered with Cielo, a leader in AI-powered franchise solutions, to transform retail advertising and franchise operations.

J&J (NYSE:JNJ) said in a statement to Seeking Alpha on Tuesday that the company has an agreement with Samsung Bioepis that allows for a biosimilar of Stelara to be launched before its patent ...

(Reuters) - Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to Stelara, J&J's blockbuster psoriasis treatment. The lawsuit ...

Johnson & Johnson (NYSE:JNJ) is suing Samsung Bioepis for breach of contract related to the launch of a biosimilar of J&J's blockbuster drug Stelara, also known as ustekinumab. The drug is used to ...